Woo et al. BMC Cancer (2021) 21:647 https://doi.org/10.1186/s12885-021-08355-w RESEARCH ARTICLE Open Access Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study Joohyun Woo1,...
In this report, we present the case of a female patient with relapsed and metastatic breast cancer, whose histology transformed from initially triplenegative to Luminal-B type (HER2 positive) (i.e., ER, PR, and HER2 positive). She underwent systematic chemotherapy, ...
MAF amplification increases the risk of breast cancer (BCa) metastasis through mechanisms that are still poorly understood yet have important clinical implications. Oestrogen-receptor-positive (ER+) BCa requires oestrogen for both growth and metastasis, albeit by ill-known mechanisms. Here we integrate...
In ERα-positive breast cancer, TRPS1 expression was positively associated with the expression of E-cadherin (P < 0.001), β-catenin(P = 0.001), ERβ (P = 0.03), and p53 (P = 0.002) status, while in ERα-negative breast cancer, TRPS1 expression was correlated with...
ER receptors are present in normal endometrial myometrium cells of the uterus in normal epithelial cells of the breast and in some breast cancer cells (about 50-60% of breast cancer patients).Researches have shown that ER positive breast cancer patients respond effectively to hormone therapy and ...
Similarly, Her2-positive tumors can be treated with drugs that target the Her2 axis. For these reasons, the NCCN task force mandate22 that ER, PR and Her2 status be measured for every new case of breast cancer. While ER, PR, and Her2 status is routinely assessed by immunohistochemistry (...
HBO1 was highly expressed in breast cancer tissues and significantly correlated with estrogen receptor α (ERα) (p<0.001) and progestational hormone (PR) (p=0.002). HBO1 protein level also correlated positively with histology grade in ERα positive tumors (p=0.016) rather than ERα negative...
Datopotamab deruxtecan(Dato-DXd) vs 化疗治疗既往经治的不可手术或转移性HR+/HER2-乳腺癌:随机Ⅲ期TROPION-Breast01试验的主要结果 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (...
2013: Clinicopathologic characteristics of STAT1 positive/interleukin-8 negative subgroup in triple negative breast cancer defined by surrogate immunohistochemistry Histology and Histopathology 28(11): 1461-1471 Mamber, S.W.; Pinter, C.D.; Okasinski, W.G.; Tunac, J.B. 1985: Comparison of ...
Moreover, since some of the analyzed tumors are IHC found to be HER-2 positive some patients with MBC and AMBC may be also candidates for herceptin treatment. 展开 关键词: breast cancer medullary breast cancer 收藏 引用 批量引用 报错 分享 ...